AstraZeneca provides this link as a service to website visitors. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Edward co-founded Acerta Pharma and served on its board until its trade-sale to AstraZeneca. Email formats. Acerta Pharma works in close collaboration with research groups in Astra Zeneca, and takes an approach to discover, develop and deliver targeted novel 1 transformational medicines for patients suffering from hematological malignancies. Developing novel targeted therapeutics for the treatment of cancer. Basilea was founded in 2000 as a spin-out from Roche and is headquartered in the heart of the life sciences hub of Basel. Designation based on positive results from two Phase III trials. The company has utilized its proprietary discovery platform to successfully develop a portfolio of competitively differentiated clinical … Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer. He is a founder of Acerta Pharma, a member of the AstraZeneca Group, and has previously served as the Chief Executive and Medical Officer. Our novel, validated approach allows Redx Pharma to progress new drug development programs with lower risk and greater speed to clinical trials. Private San Francisco Companies (Top 10K), United States Biotechnology Companies (Top 10K), Private San Francisco Bay Area Companies (Top 10K). 6. 3.5 out of 5 stars. Redx Pharma. Dr. Ahmed Hamdy is an independent Board Director and Clinical Advisor of Andes Biotechnologies. ... Acerta Pharma … Acerta Pharma BV develops drugs for oncology and autoimmune diseases. We encourage you to read the privacy policy of every website you visit. Acerta Pharma B.V. operates a biotechnology company. Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create a range of highly selective therapies for cancer. 6 reviews. Merck 9 jaar Research Fellow Merck jan. 2009 - jun. Our vision is to develop innovative hematology medicines that improve outcomes and enhance the lives of patients. Acerta Pharma was founded in 2013 and is based in San Carlos, California. Co-founder Acerta Pharma B.V. (A member of the AstraZeneca Group) feb. 2013 - jun. Before that, Dr Hamdy co-founded Acerta Pharma, a pharmaceutical development company and member of the AstraZeneca plc, and served as its head of early clinical development from January 2015 to June 2019, as chief executive officer from February 2013 to January 2015, as chief medical officer from February 2013 to January 2015 and as a member of the board from … Dr. Ahmed Hamdy is a founder of Acerta Pharma and its former Chief Executive and Medical Officer. Acerta Pharma B.V. (A member of the AstraZeneca Group) | 6,052 followers on LinkedIn. last (ex. Edward is Founder and Managing Partner at BioGeneration Ventures (BGV) and combines over 20 years of experience in venture capital, pharma licensing, drug development and translational research. Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer. Picture credits: Elastic Elastic. Three years after inception, Acerta Pharma was brought under the control of AstraZeneca after a majority equity investment in Q1 of 2016. Acerta-pharma uses 4 email formats, with first_initial '.' Acerta Pharma was acquired by AstraZeneca in February 2016. Wayne P Rothbaum is President/Managing Director/Founder at Quogue Capital LLC. Acerta founded. Snapshot. US-44652 Last Updated 11/20. Our multiparametric phospho-proteomic platform enables the characterization of activated signaling networks within complex tissues and in discrete cell subsets. Founder of Calistoga Pharmaceuticals, board member and former Chief Scientific Officer of Acerta Pharma to help guide future of company focused on ground-breaking therapy for CNS-related edema Acerta Pharma Careers and Employment | Indeed.com. Acerta Pharma provides drug discovery and development services for oncology and autoimmune diseases. All rights reserved. Now Acerta Pharma is worth $7 billion. Management Team’s Contribution. Ahmed and Raquel have a strong record in the industry. Richard Lin is the founder of Acuta Capital Partners Prior to founding Acuta Capital, Rich was a partner at Three Arch Partners, LP, a healthcare focused venture capital firm. j.smith@acerta-pharma.com) being used 73% of the time. In February 2016, AstraZeneca acquired a majority share of Acerta Pharma via a USD $4 billion investment and is a committed partner to the development of these innovative drugs. BioGeneration Ventures co-founded Acerta Pharma in 2013 with a team of seasoned drug development professionals and other investors. Show profile. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization, Auto-generated name of transaction (e.g. In February 2016, AstraZeneca acquired a majority share of Acerta Pharma via a USD $4 billion investment and is a committed partner to the development of these innovative drugs. Our Translational Medicine (TM) team are actively implementing MRD endpoints in our clinical trials to understand what treatments can drive to MRD undetectable levels. Jean-Christophe Petkovich has over 10 years of experience in data analysis, pattern recognition, statistical modelling, and machine learning. WhatsApp acquired by Facebook). This is the Acerta Pharma company profile. And that’s not just on paper. | Acerta Pharma has the responsibility of developing both internally discovered compounds as well as AstraZeneca sourced compounds for hematological malignancies. Yomara Gomez. Founded 2010. See Wayne P Rothbaum's compensation, career history, education, & memberships. Listed Company. SECTOR All content is posted anonymously by employees working at Acerta Pharma. 2019 6 jaar 5 maanden. At our recently expanded site at Oss in the Netherlands, we have core capabilities in target identification, target validation, lead generation and compound optimization. Presently, Maria Fardis occupies the position of President, Chief Executive Officer & Director at Iovance Biotherapeutics, Inc. 3.5. Dr. Hamdy has 20 years of clinical research experience in pharmaceutical drug development, seven of which were in academic medical research. Working together Acerta and AstraZeneca are focused on Innovative Clinical Strategies to enable us to combine our extensive oncology portfolio of cancer therapies. Glassdoor gives you an inside look at what it's like to work at Acerta Pharma, including salaries, reviews, office photos, and more. AstraZeneca is not responsible for the privacy policy of any third-party websites. 2013 • Developed ibrutinib from preclinical through Phase 2 in < 3 years • All three Phase 2 studies garnered Break-Through Designation and Accelerated Approvals. 2011 - jan. 2013 1 jaar 7 maanden. He is a Founder of Acerta Pharma BV and served as its Vice President of Operations, until the sale of 55% control to AstraZeneca for $4 billion. Why Join Us. Founded in Netherlands in 2012 to develop treatments for cancers and autoimmune diseases, Acerta Pharma ran in stealth mode, driving investors and over 20 clinical trials for monotherapy and in combination with other targeted molecules. +1 908-********. Thomas Turalski. In her past career she was Associate Director-Project & Portfolio Management at Gilead Sciences, Inc., Chief Operating Officer of Acerta Pharma BV and Chief Oncology Operations & Alliances at Pharmacyclics LLC. Beginning in 2012, Mr. Rothbaum served as the co-founder and largest investor of Acerta Pharma, B.V., a Dutch biotech focused on developing selective, covalent small molecules to treat cancer and inflammation. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. They co-founded Acerta Pharma in 2013 and developed BTK inhibitor, acalabrutinib (now Calquence, $511 M annual US revenue, 2020 1). Name of the organization that made the acquisition, Total amount raised across all funding rounds, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Active, Closed, Last funding round type (e.g. Founded Date 2013; Founders Ahmed Hamdy, Tjeerd Barf; Operating Status Active; Last Funding Type Series A; Legal Name AstraZeneca UK Limited; Company Type For Profit; Contact Email info@acerta-pharma.com; Phone Number 650-591-2800 Vincera’s chief executive is Ahmed Hamdy – a founder of Acerta Pharma that was acquired by AstraZeneca in 2016 in a $7 billion deal focused on cancer drug Calquence (acalabrutinib). He led the licensing negotiations with MSD and provided the seed capital. He also brought a very experienced team into the company from the outset, which led to leading US-based venture capital groups to invest into the company. Get weekly updates, new jobs, and reviews. Show profile. Jean-Christophe’s extensive work history includes writing software for safety-critical systems for leaders in the transportation industry, including QNX and Bombardier. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Most recently, Mr. Salva served as a Founder and Vice President of Operations for Acerta Pharma B.V., where he focused on key growth … Co-Founder & Clinical Operations Executive: Allard Kaptein Ph.D: Co-Founder & Executive, Discovery: Ahmed Hamdy MD: Co-Founder & Medical Executive Mr. Francisco Salva has over 20 years of experience in biotechnology finance, venture capital and operating roles. United Kingdom. Redx Pharma is a UK-based company developing new drug candidates using the broad-based potential of its innovative Redox Switch™ platform. Acerta’s lead drug, Calquence (acalabrutinib) was approved by the FDA under an accelerated approval … +1 646-********. Prior to that he was co-founder of Acerta Pharma, spinning out the covalent BTK inhibitor series from MSD into Acerta Pharma, that in 2017 received accelerated approval for mantle cell lymphoma from the FDA. Co-Founder / Head of Biology Covalution Pharma BV jul. Founders: Shay Banon, Simon Willnauer, Steven Schuurman, Uri Boness Acerta Pharma B.v. (a Member Of The Astrazeneca Group) - email id & phone of 2 top management contacts like Founder, CEO, CFO, CMO, CTO, Marketing or HR or Finance head & all company details. The Oss research centre is based in the heart of the Pivot Park Biotechnology Campus and has established relationships with both academic and commercial partners in Europe. Acerta Pharma. In 2012, Mr. Rothbaum co-founded, and was the Executive Chairman of Acerta Pharma, a private life sciences company, he later sold to AstraZeneca. The Company focuses on the discovery and development of drugs for treating oncology and autoimmune diseases. Acerta Pharma is focused on the development of covalent binding technology solutions to create therapies for cancer. He is also on the Board of Directors for Remedy Pharmaceuticals, is a Senior Advisor to Frazier Healthcare Partners, and serves as a scientific advisor to several small pharma companies. Shanghai-based Alebund Pharmaceuticals announced Monday that they raised a $60 million Series B led by Quan Capital, the VC firm from Zai Lab co-founder and CEO Samantha Du. This link will take you to a site maintained by a third party who is solely responsible for its content. Acerta Pharma was sold to Astra Zeneca in February 2016. Plexxikon USA Acquired Plexxikon® is a leader in the discovery and development of novel, small molecule pharmaceuticals. t*****@percept***.
Jamie Reed Mp,
Robert Hall Clothes Clifton Nj,
Best West Ham Players Ever,
Barnsley Council Tax Login,
Chesterfield Greyhound Stadium,
Shape Gold Mount To V-mount Regulated Battery Converter,